Predictive factors of mortality in rheumatoid arthritis-associated interstitial lung disease analysed by modified HRCT classification of idiopathic pulmonary fibrosis according to the 2018 ATS/ERS/JRS/ALAT criteria
- 期刊名称Journal of Thoracic Disease
- 作者Yamakawa, Hideaki; Sato, Shintaro; Tsumiyama, Emiri; Nishizawa, Tomotaka; Kawabe, Rie; Oba, Tomohiro; Kamikawa, Teppei; Horikoshi, Masanobu; Akasaka, Keiichi; Amano, Masako; Kuwano, Kazuyoshi; Matsushima, Hidekazu
- 卷第11卷
- 期第12期
- 印刷ISSN2072-1439
- 电子ISSN2077-6624
- 文件大小1147.70KB
- 发表时间2019-12
- DOI10.21037/jtd.2019.11.73
- 页码5247-5257
Ramucirumab and its use in the treatment of hepatocellular carcinomaTurkes, Fiona; Chau, Ian · Future Oncology · 2019
Ramucirumab as Second-Line Treatment in Patients With Advanced Hepatocellular CarcinomaZhu, Andrew X.; Baron, Ari David; Malfertheiner, Peter; Kudo, Masatoshi; Kawazoe, Seiji; Pezet, Denis; Weissinger, Florian; Brandi, Giovanni; Barone, Carlo A.; Okusaka, Takuji; Wada, Yoshiyuki; Park, Joon Oh; Ryoo, Baek-Yeol; Cho, Jae Yong; Chung, Hyun Cheol; Li, Chung-Pin; Yen, Chia-Jui; Lee, Kuan-Der; Chang, Shao-Chun; Yang, Ling; Abada, Paolo B.; Chau, Ian · JAMA Oncology · 2016
Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Prognosis, efficacy, and safety by liver disease etiologyOkusaka, T.; Blanc, J.-F.; Chau, I.; Yang, L.; Abada, P.; Zhu, A.X. · Annals of Oncology · 2016
Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma: Japanese subgroup analysis of the REACH trialKudo, Masatoshi; Hatano, Etsuro; Ohkawa, Shinichi; Fujii, Hirofumi; Masumoto, Akihide; Furuse, Junji; Wada, Yoshiyuki; Ishii, Hiroshi; Obi, Shuntaro; Kaneko, Shuichi; Kawazoe, Seiji; Yokosuka, Osamu; Ikeda, Masafumi; Ukai, Katsuaki; Morita, Sojiro; Tsuji, Akihito; Kudo, Toshihiro; Shimada, Mitsuo; Osaki, Yukio; Tateishi, Ryosuke; Sugiyama, Gen; Abada, Paolo Benjamin; Yang, Ling; Okusaka, Takuji; Zhu, Andrew Xiuxuan · Journal of Gastroenterology · 2017
Ramucirumab as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma: Analysis of Reach Patients by Albumin-Bilirubin (ALBI) GradeBlanc, J.-F.; Chan, S.L.; Park, J.O.; Ryoo, B.-Y.; Yen, C.-J.; Kudo, M.; Poon, R.; Pastorelli, D.; Baron, A.; Pfiffer, T.F.; Okusaka, T.; Kubackova, K.; Trojan, J.; Sastre, J.; Chau, I.; Abada, P.; Chang, S.-C.; Yang, L.; Zhu, A. · Journal of Hepatology · 2016
O2-8-1Ramucirumab (RAM) as second-line treatment in patients (pts) with advanced hepatocellular carcinoma (HCC): Japanese subgroup analysis of the phase III REACH trialOhkawa, Shinichi; Okusaka, Takuji; Kudo, Masatoshi; Hatano, Etsuro; Fujii, Hirofumi; Masumoto, Akihide; Furuse, Junji; Wada, Yoshiyuki; Ishii, Hiroshi; Obi, Shuntaro; Arai, Kuniaki; Kawazoe, Seiji; Yokosuka, Osamu; Ikeda, Masafumi; Ukai, Katsuaki; Morita, Sojiro; Asou, Hiroya; Abada, Paolo B.; Yang, Ling; Zhu, Andrew X. · Annals of Oncology · 2015
L03Ramucirumab (RAM) as Second-Line Treatment in Patients with Advanced Hepatocellular Carcinoma (HCC) Following First-Line Therapy with Sorafenib: Analyses from the Randomized Phase III REACH StudyBarone, C.; Brandi, G.; Daniele, B.; Villa, E.; Leo, S.; Di Fabio, F.; Aprile, G.; Colombo, M.; Sobrero, A.; Giannelli, G.; Porta, C.; Cabibbo, G.; Zhu, A.; Blanc, J.; Okusaka, T.; Chau, I.; Abada, P.; Yang, L.; Pastorelli, D. · Annals of Oncology · 2015
Response by Choi criteria to sunitinib plus octreotide LAR in a functional heavily pretreated advanced pancreatic neuroendocrine tumorGrande, Enrique; Díez, Juan José; Pachón, Vanessa; Vaz, María Ángeles; Longo, Federico; Guillén, Carmen; de Paredes, María Luisa García; Carrato, Alfredo · Anti-Cancer Drugs · 2011
Safety and Oncological Outcomes of Bevacizumab therapy in patients with advanced Colorectal Cancer and Self-Expandable Metal StentsPacheco-Barcia, Vilma; Mondéjar, Rebeca; Martínez-Sáez, Olga; Longo, Federico; Moreno, Jose Andrés; Rogado, Jacobo; Donnay, Olga; Santander, Cecilio; Carrato, Alfredo; Colomer, Ramon · Clinical Colorectal Cancer · 2019
P-235Prognostic biomarkers after colorectal liver metastasis resection: Exploratory study for VEGF, VEGFR and SPARC expressionLongo Muñoz, Federico; Cortés Salgado, Alfonso; Reguera Puertas, Pablo; Romio, Estefania; Varona, Constantino; Cristobal, Eva; Pachón Olmos, Vanessa; Ferreiro Monteagudo, Reyes; Rodriguez Garrote, Mercedes; Vaz, Maria; Gion Cortés, Maria; Madariaga Urrutia, Ainhoa; Molina Cerrillo, Javier; Martínez Saez, Olga; Villamayor Delgado, Maria; Lopez-Hervas, Pedro; Lopez-Buenadicha, Adolfo; Peromingo, Roberto; Losa, Nuria; Nuño, Javier; Palacios, Jose; Carrato, Alfredo · Annals of Oncology · 2017
First-line panitumumab plus FOLFOX4 or FOLFIRI in colorectal cancer with multiple or unresectable liver metastases: A randomised, phase II trial (PLANET-TTD)Carrato, Alfredo; Abad, Albert; Massuti, Bartomeu; Grávalos, Cristina; Escudero, Pilar; Longo-Muñoz, Federico; Manzano, José-Luis; Gómez, Auxiliadora; Safont, María José; Gallego, Javier; García-Paredes, Beatriz; Pericay, Carles; Dueñas, Rosario; Rivera, Fernando; Losa, Ferrán; Valladares-Ayerbes, Manuel; González, Encarnación; Aranda, Enrique · European Journal of Cancer · 2017
Hypotheses explaining cancer metastasisWang, Haijuan; Lin, Chen; Qian, Haili · The Chinese-German Journal of Clinical Oncology · 2012
Cancer, did you know?Yi Cheng · The Chinese-German Journal of Clinical Oncology · 2013
Ferritin involved in the tumor developmentWei, Wenqing · The Chinese-German Journal of Clinical Oncology · 2013
Guidelines for biliary stents and drainsDrapek, Lorraine C.; Kerlan Jr, Robert K.; Acquisto, Susan · Chinese Clinical Oncology · 2020
Thoughts about the origin of cancerZhang, Baihong; Yue, Hongyun · The Chinese-German Journal of Clinical Oncology · 2012
Renal ablation: current management strategies and controversiesZhong, Jim; Wah, Tze Min · Chinese Clinical Oncology · 2019
Management of glioblastoma: an Australian perspectiveSim, Hao-Wen; Nowak, Anna K.; Lwin, Zarnie; Khasraw, Mustafa · Chinese Clinical Oncology · 2020